Clinical trial
Non-small Cell Lung Cancer Registry
NCT00099541 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00099541 |
|---|---|
| Title | Non-small Cell Lung Cancer Registry |
| Official title | A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Non-Small-Cell Lung Cancer, Pleural Effusion, Malignant |
| Intervention type | Drug |
| Interventions | zoledronic acid |
| Enrollment | 300 |
| Start date | Nov 1, 2004 |
| Completion | Nov 1, 2007 |
| First posted | Dec 16, 2004 |
| Last update posted | Nov 23, 2009 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: